CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年5月25日～2025年5月31日の間に収集した論文情報を追加しました。

  1. Comparison of ileus risk in selected second-generation antipsychotics based on FAERS database.

  第二世代抗精神病薬とイレウスの関連性についての研究

  対象DB：FAERS

  2. Calcineurin Inhibitors and Risk of CNS Infections: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS).

  カルシニューリン阻害剤に関連する中枢神経系感染のリスク評価

  対象DB：FAERS

  3. Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management - What have we learned recently?

  ベバシズマブとアルキル化剤の安全性プロファイル比較

  対象DB：FAERS

  4. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.

  スルファメトキサゾールの安全性評価と臨床研究の必要性

  対象DB：FAERS

  5. Gastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study.

  SNRIに関連する胃腸の有害事象の評価

  対象DB：FAERS

  6. Signal Mining and Analysis of Drug-Induced Myelosuppression: A Real-World Study From FAERS.

  薬剤誘発性骨髄抑制のリスク評価とシグナル検出

  対象DB：FAERS

  7. Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system.

  バクロフェンの神経安全性とリスクの評価

  対象DB：FAERS

  8. Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database.

  アロマターゼ阻害剤と皮膚の有害事象のリスク評価

  対象DB：FAERS

  9. Sodium-glucose cotransporter-2 inhibitors and ketoacidosis in heart failure: analysis of US Adverse Event Reporting System (FAERS).

  心不全におけるSGLT-2阻害剤とケトアシドーシスの分析

  対象DB：FAERS

  10. Post-marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: A disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) database.

  セムグリーとランタスの安全性シグナルをFDA報告から特定

  対象DB：FAERS

  11. Treatment of Opioid-Induced Constipation: Inducing Laxation and Understanding the Risk of Gastrointestinal Perforation.

  オピオイド誘発性便秘の治療とそのリスクの管理

  対象DB：FAERS

  12. Unveiling the hidden risks: analysis of adverse drug reactions associated with probiotics from the faers database-quality improvement study.

  プロバイオティクスに関連する有害薬物反応のFAERS分析

  対象DB：FAERS

  13. Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system.

  妊娠中の女性の抗てんかん薬のリスク評価

  対象DB：FAERS

  14. A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023.

  プロバイオティクス関連の有害事象のFAERS分析

  対象DB：FAERS

  15. Real-World Safety Profile of Proton Pump Inhibitors in Infants as Reported in the FDA Adverse Event Reporting System (FAERS): Tiny Tummies, Key Decisions.

  乳児向けPPIの安全性評価とRWD分析

  対象DB：FAERS

  16. Disproportionality Analysis of Renal Adverse Events Associated with a Combination of Immune Checkpoint Inhibitors and Acid-Suppressing Agents-A Pharmacovigilance Study Based on the FAERS Database.

  ICIとPPIの併用時の腎臓有害事象を分析

  対象DB：FAERS

  17. Adverse Drug Reactions Associated with Concomitant Use of Calcium Channel Blockers and Cocaine: An Analysis of FDA Adverse Events Reporting System Data.

  カルシウム拮抗剤とコカインの併用調査

  対象DB：FAERS

  18. Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database.

  バロキサビルマルボキシルの安全性データ分析

  対象DB：FAERS

  19. Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database.

  非定型抗精神病薬に関連するNMSの分析

  対象DB：FAERS

  20. Drug Safety Signals for Pediatric Osteopenia and Osteoporosis: Disproportionality Analysis of USFDA Adverse Event Reporting System Analysis.

  小児の骨粗しょう症：米FDA副作用報告分析

  対象DB：FAERS

  21. Drug-related suicidal ideation in the K-12 population: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS) database.

  K-12の若者における薬関連の自殺念慮のリスク

  対象DB：FAERS

  22. Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database.

  FAERSデータから薬剤誘発性光感受性を分析

  対象DB：FAERS

  23. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.

  GLP-1受容体作動薬の神経系副作用を分析

  対象DB：FAERS

  24. Peripheral Neuropathy in Patients With Ovarian Cancer Administrating Poly ADP-Ribose Polymerase Inhibitors: A Real-World Study Based on Bayesian Disproportionality Analysis of the US Food and Drug Administration Adverse Event Reporting System.

  卵巣がん治療剤の副作用を解析

  対象DB：FAERS

  25. Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases.

  ペメトレキセドの安全性を包括的に評価

  対象DB：JADER

  26. Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab.

  偏頭痛予防のmAbsの安全性を分析

  対象DB：EudraVigilance

  27. Valproic Acid-Induced Congenital Disorders, an Analysis in EudraVigilance and a Literature Review of Valproic Acid Utilization During Pregnancy.

  VPA使用による先天性障害リスクを分析

  対象DB：EudraVigilance

  28. Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis.

  うつ病に対するエスケタミンの安全性を評価

  対象DB：EudraVigilance

  29. Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance.

  COVID-19ワクチンの市販後調査が重要

  対象DB：EudraVigilance

  30. Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study.

  臓器移植における免疫抑制剤の有効性評価

  対象DB：EudraVigilance

  31. Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database.

  SARS-CoV-2ワクチンの副反応を分析

  対象DB：EudraVigilance

  32. Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela).

  犬の関節疾患に対するベディンベツマブのリスク分析

  対象DB：EudraVigilance

  33. BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase.

  妊娠中のTKI使用に関するリスク分析

  対象DB：VigiBase

  34. Characterizing pharmacobezoar formation: a descriptive analysis from VigiBase.

  薬物べゾアールに関するグローバルな分析提供

  対象DB：VigiBase

  35. Pregabalin Safety in Pregnancy: A Disproportionality Analysis of VigiBase Spontaneous Reporting System.

  妊娠中のプレガバリン使用の安全性評価

  対象DB：VigiBase

  36. Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing.

  小児の予防接種後GI系AEFI検出のベイズモデル評価

  対象DB：VigiBase

  37. Prognosis of patients with aneurysmal subarachnoid hemorrhage treated with fasudil hydrochloride-cilostazol combination therapy: A cross-sectional analysis of a nationwide inpatient database, 2016 to 2020.

  併用治療が脳動脈瘤後の予後改善に寄与

  対象DB：DPC

  38. Children Comorbidity Score, a Simple Predictor for In-hospital Mortality: A Nationwide Inpatient Database Study in Japan.

  小児の合併症スコアCCS、死亡率予測に有効

  対象DB：DPC

  39. Association between Acute Care Accessibility and in-Hospital Mortality among Patients with Acute Ischemic Stroke.

  脳卒中の死亡率、ケア密度と距離影響

  対象DB：DPC

  40. The maternal postnatal six-week check in women with epilepsy: Does the prevalence or subsequent postpartum health differ from the general postnatal population?

  産後6週間検診が健康問題の検出に影響

  対象DB：CPRD

  41. Cardiovascular and venous thromboembolic events in systemic sclerosis: epidemiological analysis of the Clinical Practice Research Datalink.

  全身性硬化症患者は心血管疾患や血栓塞栓症のリスクが高い

  対象DB：CPRD

  42. Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England.

  英国で第二世代BIが糖尿病患者の治療費を削減する効果が示された

  対象DB：CPRD

  43. Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease.

  CVD患者の治療強化閾値は2.0が最適

  対象DB：CPRD

  44. Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.

  FH女性は特に30?50歳でCVD罹患率が高い

  対象DB：CPRD

  45. The prediction of suicide in severe mental illness: development and validation of a clinical prediction rule (OxMIS).

  OxMISは重度精神疾患患者の自殺予測に有用

  対象DB：CPRD

  46. Prediction of violent reoffending in prisoners and individuals on probation: a Dutch validation study (OxRec).

  OxRecは再調整で再犯リスク予測に有用

  対象DB：CPRD

  47. Prognosis of undiagnosed chest pain: linked electronic health record cohort study.

  原因不明の胸痛患者は心血管リスクが高い

  対象DB：CPRD

  48. Cancer as a risk factor for urinary tract calculi: a retrospective cohort study using 'The Health Improvement Network' : Cancer and urinary tract calculi.

  がん患者は尿路結石のリスクが高い

  対象DB：THIN

  49. The diagnostic status of chronic kidney disease in a real-world database in Japan: CHECK-CKD.

  CKD診断率は低く早期検出に課題

  対象DB：DeSC

  50. Difference in Age- and Sex-adjusted Prevalence of Diseases between Employees and Nonemployees with Health Insurance in Japan.

  保険種別で有病率に有意差あり

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み